Imidazoline receptor agonist drugs: A new approach to the treatment of systemic hypertension

Journal of Clinical Pharmacology

Volumn 36, Issue 2, 1996, Pages 98-111

  Yu, Austin ^a   Frishman, William H ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 1H 3 BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 9 (3 METHYL 2 BUTENYLOXY) 1H 3 BENZAZEPINE; ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; APRACLONIDINE; ATENOLOL; BRIMONIDINE; CAPTOPRIL; CIMETIDINE; CIRAZOLINE; CLONIDINE; EFAROXAN; GUANABENZ; GUANFACINE; IDAZOXAN; IMIDAZOLEACETIC ACID; IMIDAZOLINE RECEPTOR; LOFEXIDINE; MOXONIDINE; NAPHAZOLINE; NIFEDIPINE; OXYMETAZOLINE; PHENOXYBENZAMINE; PHENTOLAMINE; PIPEROXAN; PRAZOSIN; RILMENIDINE; UNINDEXED DRUG; YOHIMBINE;

ANTIHYPERTENSIVE ACTIVITY; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN PROTECTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SCREENING; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY FAILURE; NEUROPROTECTION; NONHUMAN; REVIEW;

EID: 0029972846     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04174.x     Document Type: Review

References (100)

1. Safar ME, Pannier BM: Rilmenidine. ,n, Messerli R: Cardiovascular Drug Therapy. Philadelphia: WB Saunders, 1990; 667-676.
2. 2-adrenoceptor agonist rilmenidine. Am J Cardiol 1988; 61:6D-14D.
3. Koenig-Berard E, Tierney C, Beau B, Delbarre G, Lhoste F, Labrid C: Cardiovascular and central nervous system effects of rilmenidine (S-3341) in rats. Am J Cardiol 1988; 61:22D-31D.
4. Velasco M, Luchsinger A: Central acting antihypertensive drugs: past, present, and future. Am J Ther 1995; 2:255-257.
5. 2 type by B-HT 933. Eur J Pharmacol 1980; 63: 199-202.
6. Singlas E, Ehrhardt JD, Zech P, Pozet N, Genissel P: Pharmacokinetics of rilmenidine. Am J Cardiol 1988; 61:54D-59D.
7. Dontenwill M, Tibirica E, Greney G, Bennai F, Feldman J, Stutzmann J, et al: Role of imidazoline receptors in cardiovascular regulation. Am J Cardiol 1994; 74:3A-6A.
8. Bousquet P, Feldman J, Schwartz J: Central cardiovascular effects of alpha-adrenergic drugs: difference between catecholamines and imidazolines. J Pharmacol Exp Ther 1984; 230:230-236.
9. Feldman F, Tibirica E, Brica G, Dontenwill M, Belcourt A, Bosquet P: Evidence for the involvement of imidazoline receptor in the central hypotensive effect of rilmenidine in the rabbit. Br J Pharmacol 1990; 100:600-604.
10. Reis D, Regunathan S, Golanov G, Feinstein D: Protection of focal ischemic infarction by rilmenidine in the animal: evidence that interactions with central imidazoline receptors may be neuroprotective. Am J Cardiol 1994; 74:25A-30A.
11. Regunthan S, Meeley MP, Reis DJ: Expression on nonadrenergic imidazoline sites in chromaffin cell and mitochondrial membranes of bovine adrenal medulla. Biochem Pharmacol 1993; 45: 1667-1675.
12. Michel MC, Insel PA: Are there multiple imidazoline binding sites? Trends Pharmacol Sci 1989; 10:342-344.
13. Ernsberger P, Damon TH, Graf LM, Schaffer S, Christen MO: Moxonidine, a central acting antihypertensive agent, is selective for I-1 imidazoline sites. J Pharmacol Exp Ther 1993; 264:172-182.
14. Gomez RO, Ernsberger P, Feinland G, Reis DJ: Rilmenidine lowers arterial pressure via imidazoline receptors in the brainstem C1 area. Eur J Pharmacol 1991; 195:181-191.
15. Ernsberger P, Meeley MP, Mann JJ, Reis DJ: Clonidine binds to imidazoline binding sites as well as alpha 2-adrenoceptors in the ventrolaterial medulla. Eur J Pharmacol 1987; 134:1-13.
16. 2-adrenoceptors and imidazoline binding sites: distribution of imidazoline binding sites in rat brain. Brain Res 1990; 514:15-21.
17. Reis DJ, Ruggiero DA, Morrison SJ: The C1 area of the rostral ventrolateral medulla: a critical brainstem region for control of resting and reflex integration of arterial pressure. Am J Hypertens 1989; 291:2363S-2374S.
18. 1 sites): putative G-protein-linked receptors (abstract). FASEB J 1991; 5:A1006.
19. Maiese K, Pek L, Berger SB, Reis DJ: Reduction in focal cerebral ischemia by agents acting at imidazole receptors. J Cereb Blood Flow Metab 1992; 12:53-63.
20. Yamamato S, Golanov EV, Berger SB, Reis DJ: Inhibition of nitric oxide synthesis increases focal ischemic infarction in rat. J Cereb Blood Flow Metab 1992; 12:717-726.
21. 2-adrenergic receptor or a new receptor? Eur J Pharmacol 1990; 183:853-854.
22. Petrusewica J, Kaliszan R: Human blood platelet alpha adrenoceptor in view of the effects of various imidazol(in)e drugs on aggregation. Gen Pharmacol 1991; 22:819-823.
23. Piletz JE, Sletten K: Nonadrenergic imidazoline binding sites on human platelets. J Pharmacol Exp Ther 1993; 267:1493-1502.
24. 2-adrenergic drugs also bind with high affinity to a non-adrenergic site. Mol Pharmacol 1989; 35:324-330.
25. Diamant S, Eldar-Geva T, Atlas D: Imidazoline binding sites in human placenta: evidence for heterogeneity and a search for physiological function. Br J Pharmacol 1992; 106:1019-1027.
26. 2-adrenergic binding sites in basolateral membranes from human kidneys. Eur J Pharmacol 1991; 206:23-31.
27. Coupry I, Atlas D, Pedevin RA, Uzielli I, Parini A: Imidazoline-guanidinium receptive sites in renal proximal tubule: asymmetric distribution, regulation by cations and interaction with an endogenous clonidine displacing substance. J Pharmacol Exp Ther 1989; 252:293-299.
28. Ernsberger P, Feinland G, Meeley MP, Reis DJ: Characterization and visualization of clonidine-sensitive imidazoline sites in rat kidney which recognize clondine-displacing substance. Am J Hypertens 1990; 3:90-97.
29. Mallard NJ, Hudson AL, Nutt DJ: Characterization and autoradio-graphical localization of non-adrenoceptor idazoxan binding sites in the rat brain. Br J Pharmacol 1992; 106:1019-1027.
30. 2-adrenergic receptors in bovine cerebral cortex (abstract). Soc Neurosci Abstr 1992; 18:591.
31. Michenfelder JD, Milde JH, Sundt TM Jr: Cerebral protection by barbiturate anesthesia: use after middle cerebral artery occlusion in Java monkeys. Arch Neurol 1976; 33:345-350.
32. Regunathan S, Feinstein DL, Reis DJ: Expression of nonadrenergic sites in rat cerebral cortical astrocytes. J Neurosci Res 1993; 34:681-688.
33. Wang H, McGowan D, Regunathan S, Bramwell S, Li G. Reis DJ: Idazoxan-specific antiserum recognizes an endogenous clonidine-displacing substance in human serum and CSF (abstract). Hypertension 1993; 22:417.
34. Atlas D, Burstein Y: Isolation of an endgenous clonidine-displacing substance from rat brain. FEBS Lett 1984; 170:387-390.
35. Atlas D, Burstein Y: Isolation and partial purification of a clonidine-displacing endogenous brain substance. Eur J Biochem 1984; 144:287-293.
36. Meeley MP, Ernsberge PR, Granata AR, Reis DJ: An endogenous clonidine-displacing substance from bovine brain: receptor binding and hypotensive actions in the ventrolateral medulla. Life Sci 1986; 38:1119-1126.
37. 3H]-clonidine to identify imidazoline receptors in the rabbit brainstem. Br J Pharmacol 1993; 110:1537-1543.
38. Bricca G, Dontenwill M, Molines A, Feldman J, Tibirica E, Belcourt A, Bousquet P: Rilmenidine selectivity for imidazoline receptors in human brain. Eur J Pharmacol 1989; 163:373-377.
39. Guyenet PG, Cabot JC: Inhibition of sympathetic preganglionic neurons by catecholamines and clonidine: mediation by an α-adrenergic receptor. J Neurosci 1981; 1:908-917.
40. Sun MK, Guyenet PG: Effect of clonidine and gamma-amniobutyric acid on the discharges of medullo-spinal sympathoexcitatory neurons in the rat. Brain Res 1986; 368:1-17.
41. 2-agonists. J Cardiovasc Pharmacol 1986; 8(Suppl 8): S38-S44.
42. Ernsberger P, Guiliano R, Willette RN, Reis DJ: Role of imidazoline receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther 1990; 253:408-414.
43. Ernsberger P, Westbrooks L, Christen O, Schafer SG: A second generation of centrally acting antihypertensive agents act on putative I1-imidazoline receptors. J Cardiovasc Pharmacol 1992; 20: S1-S10.
44. Sannajust F, Head G: Involvement of imidazoline-preferring receptors in regulation of sympathetic tone. Am J Cardiol 1994; 74: 7A-19A.
45. Deckert V, Lachaud V, Parini A, Elghozi JL: Contribution of alpha-2-adrenoceptors to the central cardiovascular effects of clonidine and S8350 in anaesthetized rats. Clin Exp Pharmacol Physiol 1991; 18:401-408.
46. 2-adrenoceptor blockade by (imidazolinyl-2-)-2-benzodioxane 1-4 (170150): antagonistic action on central effects of clonidine. Arch Int Pharmacodyn Ther 1981; 254:262-270.
47. Li P, Penner SB, Smyth DD: Attenuated renal response to moxonidine and rilmenidine on kidney one-clip hypertensive rats. Br J Pharmacol 1994; 112:200-206.
48. Kline R, van der Mark J, Cechetteo D: Natriuretic effect of rilmenidine in anesthetized rats. Am J Cardiol 1994; 74:20A-24A.
49. 2-adrenergic receptor antagonist, decreases neuronal damage in the rat brain. J Cereb Blood Flow Metab 1989; 9:171-174.
50. 2-adrenergjc receptor antagonist idazoxan: influence of time of administration and possible mechanisms of action. J Cereb Blood Flow Metab 1989; 10:885-894.
51. Ruggiero DA, Milner TA, Wang H, Regunathan S, Reis DJ: Imidazoline receptor-associated binding protein in the central nervous system (abstract). Soc Neurosci Abstr 1992; 18:591.
52. Regunathan S, Evinger MJ, Meeley MP, Reis DJ: Effect of clonidine and other imidazole-receptor binding agents on second messenger systems and calcium influx in bovine adrenal chromaffin cells. Biochem Pharmacol 1991; 42:2011-2018.
53. + transport and intracellular pH in renal proximal tubule cells. Biochem Biophys Acta 1990; 1024:173-178.
54. Siesjo BK: Pathophysiology and treatment of focal cerebral ischemia. I. Pathophysiology. J Neurosurg 1992; 77:167-184.
55. Imaizumi S, Woolworth V, Fichman RA, Chan PH: Liposome-entrapped superoxide dismutase reduces cerebral infarction in cerebral ischemia in rats. Stroke 1990; 21:1312-1317.
56. Liu TH, Beckman JS, Freeman BA, Kogan EL, Hsu CY: Polyethylene glycol-conjugated superoxide dismutase and catalase reduce ischemic brain injury. Am J Physiol 1989; 256:H589-H593.
57. Kucharzyk J, Chew W, Derugin J, Moseley M, Rollin C, Berry I, Norman D: Nicardipine reduces ischemic brain injury: magnetic resonance imaging/spectroscopy study in cats. Stroke 1989; 20: 268-274.
58. Jacewicz M, Brint S, Tanabe J, Wang X-J, Pulsinelli WA: Nimodipine pretreatment improves cerebral blood flow and reduces brain edema in conscious rats subjected to focal cerebral ischemia. J Cereb Blood Flow Metab 1990; 10:903-913.
59. Park CK, Nehis DG, Teasdale GM, McCulloch J: Focal ischemia of the rat brain: autoradiographic determination of cerebral glucose utilization, glucose content, and blood flow. J Cereb Blood Flow Metab 1986; 9:617-622.
60. Ozyurt E, Graham DI, Woodruff GN, McCulloch J: Protective effect of the glutamate antagonist, MK-801, in focal cerebral ischemia in the cat. J Cereb Blood Flow Metab 1988; 8:138-143.
61. Smith A, Hoff J, Nielsen S, Larson C: Barbiturate protection in acute focal cerebral ischemia. Stroke 1974; 5:1-7.
62. Onesti ST, Baker CJ, Sun PP, Solomon RA: Transient hypothermia reduces focal ischemic brain injury in the rat. Neurosurgery 1991; 29:369-373.
63. Wikber JE, Uhlen S: Further characterization of the guinea pig cerebral cortex idazoxan receptor solubilization, distinction from the imidazole site, and demonstration of cirazoline as an idazoxan receptor selective drug. J Neurochem 1990; 55:192-203.
64. Raley-Susman KM, Lipton P: In vitro ischemia and protein synthesis in the rat hippocampal slice: the role of calcium and NMDA receptor activation. Brain Res 1990; 515:27-28.
65. Amagasa M, Ogawa A, Yoshimoto T: Effect of calcium and calcium antagonists against deprivation of glucose and oxygen in guinea pig hippocampal slices. Brain Res 1990; 526:1-7.
66. Fillastre JP, Letac B, Galinier F, LeBihan G, Schwartz J: A multicenter double-blind comparative study of rilmenidine and clonidine in 333 hypertensive patients. Am J Cardiol 1988; 61 (Suppl):81D-85D.
67. Ostermann G, Brisgand B, Schmitt J, Fillastre JP: Efficacy and acceptability of rilmenidine for mild to moderate systemic hypertension. Am J Cardiol 1988; 61:76D-80D.
68. Beau B, Mahieux F, Paraire M, Laurin S. Brisgand B, Vitou PH: Efficacy and safety of rilmenidine for arterial hypertension. Am J Cardiol 1988; 61:95D-102D.
69. Pillion G, Fevier B, Codis P, Schutz D: Long-term control of blood pressure by rilmenidine in high-risk populations. Am J Cardiol 1994; 74:58A-65A.
70. Mpoy M, Vandeleene B, Ketelslegers JM, Lambert A: Treatment of systemic hypertension in insulin-treated diabetes mellitus with rilmenidine. Am J Cardiol 1988; 61:91D-94D.
71. Lins R, Daelemans R, Dratwa M, Verbeeren D, Sennesael J, Brisgand B, Lameire N: Acceptability of rilmenidine and long-term surveillance of plasma concentration in hypertensive patients with renal insufficiency. Am J Med 1989, 87(Suppl 3C):41S-45S.
72. Aparicio M, Dratwa M, El Esper N, Fillastre JP, Levaltier B, Lins R, Meyrier A, Mignon R, Rykelynck P, Sennesael J: Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients. Am J Cardiol 1994; 74:43A-50A.
73. Trimarco B, Rosiello G, Sarno D, Lorino G, Rubattu S, DeLuca N, Volpe M: Effects of one-year treatment with rilmenidine on systemic hypertension-induced left ventricular hypertrophy in hypertensive patients. Am J Cardiol 1994; 74:36A-42A.
74. Galley P, Manciet G, Hessel JL, Michel JP: Antihypertensive efficacy and acceptability of rilmenidine in elderly hypertensive patients. Am J Cardiol 1988; 61:86D-90D.
75. Pelemans W, Verhaeghe J, Creytens G, Coupez G, Van Dessel A, Opsomer M, Corcoran C: Efficacy and safety of rilmenidine in elderly patients: a double blind comparison with hydrochlorothiazide. Am J Cardiol 1994; 74:51A-57A.
76. Dallocchio M, Gosse P, Grollier G, Morand P, Drici M, Corcoran C: La rilmenidine, un nouvel antihypertenseur dans le traitement de premiere intention de l'hypertension arterielle essentielle: etude multicentrique en double aveugle contre atenolol. Presse Med 1991; 20:1265-1271.
77. Fiorentini C, Guillet C, Guzaai M: Etude multicentrique en double aveugle comparant la rilmenidine 1 mg et 1-hydrochlorothiazide 25 mg chez 244 patients. Arch Mal Coeur 1989; 82:39-46.
78. The UK Working Party on Rilmenidine: Rilmenidine in mild to moderate essential hypertension: a double blind, randomized, parallel group, multicenter comparison with methyldopa in 157 patients. Clin Ther Res 1990; 47:194-211.
79. Harron DWG: Antihypertensive drugs and baroreflex sensitivity. N Engl J Med 1989; 321:952-957.
80. Trimarco B, DeLuca N, Ricciardelli B, Rosiello G, Volpe M, Condorelli G, et al: Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophy. Am J Cardiol 1988; 62:745-750.
81. Trimarco B, DeLuca N, Rosiello G, Ricciardelli B, Betocchi S, Perrone Filardi P, et al: Improvement in diastolic function after reversal of left ventricular hypertrophy induced by long-term antihypertensive treatment with tertatolol. Am J Cardiol 1989; 64: 745-751.
82. Hachamovitch R, Strom JA, Sonnenblick EH, Frishman WH: Left ventricular hypertrophy in hypertension and the effects of antihypertensive drug therapy. Curr Probl Cardiol 1988; 13:371-421.
83. Dahlof B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5:95-110.
84. Trimarco B, Ricciardelli B, DeLuca N, DeSimone A, Cuocolo A, Galva M, et al: Participation of endogenous catecholamines in the regulation of left ventricular mass in progeny of hypertensive patients. Circulation 1985; 72:38-46.
85. 1-imidazoline agonist moxonidine administered into the rostral ventrolateral medulla. J Cardiovasc Pharmacol 1992; 20 (Suppl 4):S11-S15.
86. MacPhee GJA, Howie CA, Elliott HL, Reid JL: A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects. Br J Clin Pharmacol 1992; 33: 261-267.
87. Mitrovic V, Patyna W, Huting J, Schepper M: Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991; 5:967-972.
88. Kirch H, Hutt H-J, Planitz N: Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients. J Clin Pharmacol 1990; 30:1088-1095.
89. Huting J, Mitrovic V, Behavar J, Schlepper M: Vergleich der wirkungen von moxonidin und nifedipin auf die linksventrikulare function bei monotherapie der essentiellen hypertonie. Jerz/ Kreislauf 1992; 24:132-137.
90. Eichstadt G, Gatz G, Schroder R, Kreuz D: Linksventrikulare hypertrophieregression unter einer therapie mit moxonidin. J Pharmacol Ther 1991; 1:12-17.
91. Schwartz W, Kandziora J: Langzeiterfahrungen mit moxonidin, einem neuen antihypertensivum. Fortschr Med 1990; 108: 616-620.
92. Planitz V: Comparison of moxonidine and clonidine HCl in treating patients with hypertension. J Clin Pharmacol 1987; 27:46-51.
93. Planitz V: Crossover comparison of moxonidine and clonidine in mild to moderate hypertension. Eur J Clin Pharmacol 1984; 27: 147-152.
94. Prichard BNC, Simmons R, Rooks MJ, Haworth DA, Laws D, Wonnacott S: A double-blind comparison of moxonidine and atenolol in the management of patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1992; 20(Suppl 4):S45-S49.
95. Wolf R: The treatment of hypertensive patients with a calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol 1992; 20(Suppl 4):S42-S44.
96. Mangiameli S, Privitera A, Jonte G, Low-Kroger A: Moxonidine versus nifedipine retard in the treatment of mild to moderate hypertension. Z Allgemeinmed 1992; 68:862-866.
97. Ollivier JP, Christen MO, Schafer SG: Moxonidine: a second generation of centrally acting drugs. An appraisal of clinical experience. J Cardiovasc Pharmacol 1992; 20(Suppl 4]:S31-S37.
98. Chrisp P, Faulds D: Moxonidine: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1992; 44:993-1012.
99. Planitz V: Intra-individual comparison of moxonidine and prazosin in hypertensive patients. Eur J Clin Pharmacol 1986; 229: 645-650.
100. Weinmann H-J, Rudolph M: Clinical pharmacokinetics of moxonidine. J Cardiovasc Pharmacol 1992; 20(Suppl 4):S37-S44.